menu
    • menu
    [{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Eucure Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"Toripalimab","moa":"||CD40L receptor (CD40)","graph1":"Oncology","graph2":"Phase II","graph3":"ISU ABXIS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ISU ABXIS \/ ISU ABXIS","highestDevelopmentStatusID":"8","companyTruncated":"ISU ABXIS \/ ISU ABXIS"},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"ISU302","moa":"Erythropoietin receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"ISU ABXIS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ISU ABXIS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ISU ABXIS \/ Undisclosed"},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"ISU302","moa":"Erythropoietin receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"ISU ABXIS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"ISU ABXIS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ISU ABXIS \/ Undisclosed"},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"ISU302","moa":"Erythropoietin receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"ISU ABXIS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ISU ABXIS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ISU ABXIS \/ Undisclosed"},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Catalyst Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"ISU304","moa":"Filgrastim receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ISU ABXIS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ISU ABXIS \/ Catalyst Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"ISU ABXIS \/ Catalyst Biosciences"},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Agalsidase Beta","moa":"Globotriosylceramide","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ISU ABXIS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ISU ABXIS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ISU ABXIS \/ Undisclosed"},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Petrovax","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Enzyme","year":"2022","type":"Licensing Agreement","leadProduct":"Agalsidase Beta","moa":"Globotriosylceramide","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ISU ABXIS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ISU ABXIS \/ Petrovax","highestDevelopmentStatusID":"15","companyTruncated":"ISU ABXIS \/ Petrovax"},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Petrovax","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"RUSSIA","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Agalsidase Beta","moa":"Globotriosylceramide","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ISU ABXIS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ISU ABXIS \/ ISU ABXIS","highestDevelopmentStatusID":"15","companyTruncated":"ISU ABXIS \/ ISU ABXIS"},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Abcertin","moa":"Glucocerebroside","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ISU ABXIS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ISU ABXIS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ISU ABXIS \/ Undisclosed"},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Imiglucerase","moa":"Glucocerebroside","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ISU ABXIS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ISU ABXIS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ISU ABXIS \/ Undisclosed"},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Imiglucerase","moa":"Glucocerebroside","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ISU ABXIS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ISU ABXIS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ISU ABXIS \/ Undisclosed"},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Abciximab","moa":"Integrin alpha-IIb\/beta-3 | Integrin alpha-V\/beta-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ISU ABXIS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ISU ABXIS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ISU ABXIS \/ Undisclosed"},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"ISU104","moa":"monoclonal antibodies: tumors","graph1":"Oncology","graph2":"Phase I","graph3":"ISU ABXIS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ISU ABXIS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ISU ABXIS \/ Undisclosed"},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Eucure Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"ISU ABXIS","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ISU ABXIS \/ ISU ABXIS","highestDevelopmentStatusID":"2","companyTruncated":"ISU ABXIS \/ ISU ABXIS"}]

    Find Clinical Drug Pipeline Developments & Deals by ISU ABXIS

    Menu

    ISU ABXIS

    EVENTS

    • Webinars & Exhibitions

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ISU ABXIS

                            South Korea arrow
                            AAPS
                            Not Confirmed

                            ISU ABXIS

                            South Korea arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Agalsidase Beta

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease

                            Details : Fabagal (Agalsidase Beta) is a Enzyme drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Fabry Disease.

                            Product Name : Fabagal

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            October 12, 2023

                            Lead Product(s) : Agalsidase Beta

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ISU ABXIS

                            South Korea arrow
                            AAPS
                            Not Confirmed

                            ISU ABXIS

                            South Korea arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Agalsidase Beta

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Recipient : Petrovax

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Fabagal® for Fabry Disease Management is Now Available in Russia

                            Details : Fabagal (agalsidase-beta) is a recombinant analogue of human alpha-galactosidase A and is produced by recombinant DNA technology. It is approved for the treatment of fabry disease in adults and children from 8 years old.

                            Product Name : Fabagal

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            October 02, 2023

                            Lead Product(s) : Agalsidase Beta

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Recipient : Petrovax

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ISU ABXIS

                            South Korea arrow
                            AAPS
                            Not Confirmed

                            ISU ABXIS

                            South Korea arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Eucure Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            ucure Biopharma, a Subsidiary of Biocytogen, Announces Partnership with ISU ABXIS for the Development of Tri-s...

                            Details : YH003 is a humanized IgG2 agonistic CD40 antibody. Whether used as a single agent or in combination with anti-PD-1 monoclonal antibody drugs, YH003 demonstrated strong anti-tumor effects against multiple tumor.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 01, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Eucure Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ISU ABXIS

                            South Korea arrow
                            AAPS
                            Not Confirmed

                            ISU ABXIS

                            South Korea arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : YH003,Toripalimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Eucure Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Eucure Biopharma, a Subsidiary of Biocytogen, Announces Partnership with ISU ABXIS for the Development of Tri-...

                            Details : Under the terms of the agreement, ISU ABXIS will utilize the sequence of YH003, Biocytogen’s humanized agonistic anti-CD40 antibody currently in phase II clinical trials, to construct a few groups of tri-specific antibodies and develop cancer drugs for...

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            October 31, 2022

                            Lead Product(s) : YH003,Toripalimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Eucure Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ISU ABXIS

                            South Korea arrow
                            AAPS
                            Not Confirmed

                            ISU ABXIS

                            South Korea arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Imiglucerase

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Isu Abxis, Ranked First for Two Consecutive Years in the Algerian Gaucher Disease Treatment Bidding

                            Details : Abcertin (Imiglucerase) is an orphan drug independently developed by Isu Abxis, is an Enzyme Replacement Therapy (ERT) treatment for Gaucher disease with the same ingredient name as Cerezyme.

                            Product Name : Abcertin

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            October 22, 2022

                            Lead Product(s) : Imiglucerase

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ISU ABXIS

                            South Korea arrow
                            AAPS
                            Not Confirmed

                            ISU ABXIS

                            South Korea arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Imiglucerase

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Isu Abxis Expects 100% Exclusive Treatment for Gaucher Disease in Algeria

                            Details : Abcertin (Imiglucerase) is an orphan drug independently developed by Isu Abxis, is an Enzyme Replacement Therapy (ERT) treatment for Gaucher disease with the same ingredient name as Cerezyme.

                            Product Name : Abcertin

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            August 12, 2022

                            Lead Product(s) : Imiglucerase

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            ISU ABXIS

                            South Korea arrow
                            AAPS
                            Not Confirmed

                            ISU ABXIS

                            South Korea arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Agalsidase Beta

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Petrovax

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ISU ABXIS has Signed a License Agreement for “fabagal” a Therapeutic for Fabry Disease, with NPO Petrovax ...

                            Details : Under the agreement, Petrovax gains access to Fabagal (agalsidase beta), indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency).

                            Product Name : Fabagal

                            Product Type : Enzyme

                            Upfront Cash : Undisclosed

                            January 26, 2022

                            Lead Product(s) : Agalsidase Beta

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Petrovax

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            ISU ABXIS

                            South Korea arrow
                            AAPS
                            Not Confirmed

                            ISU ABXIS

                            South Korea arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abcertin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase I Study to Compare Abcertin and EU-sourced Cerezyme® in Healthy Volunteers

                            Details : Abcertin is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Gaucher Disease.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            March 09, 2021

                            Lead Product(s) : Abcertin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            ISU ABXIS

                            South Korea arrow
                            AAPS
                            Not Confirmed

                            ISU ABXIS

                            South Korea arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ISU104

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors

                            Details : ISU104 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 11, 2018

                            Lead Product(s) : ISU104

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            ISU ABXIS

                            South Korea arrow
                            AAPS
                            Not Confirmed

                            ISU ABXIS

                            South Korea arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ISU304

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Catalyst Biosciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients

                            Details : ISU304 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hemophilia B.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 14, 2017

                            Lead Product(s) : ISU304

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Catalyst Biosciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth